In breast cancer, Spanish guidelines suggest that an optimal gene panel should detect AKT1, PIK3CA, PTEN, and ESR1 mutations and FGFR1 amplification, in addition to studying estrogen receptor, progesterone receptor, HER2, and BRCA1/2, although NGS is still only considered a research tool [68]. Here, ESR1 is linked to breast carcinoma.